1677 results about "Bipyridine" patented technology

An organic electroluminescent display element has at least a positive electrode, an organic luminescent film, an electron injection layer and a negative electrode. Each of the positive and negative electrodes is formed of a transparent conductive film, the electron injection layer is formed of a thin transparent film made of a halogenide of an alkali metal or an alkaline earth metal, or an organic metal complex containing an alkali metal or an alkaline earth metal as a metal, and the organic metal complex is at least one complex selected from the group consisting of acetylacetonate complexes, alpha-nitroso-beta-naphthol complexes, salicylaldoxime complexes, cupferron complexes, benzoinoxime complexes, bipyridine complexes, phenanthroline complexes, crown complexes, proline complexes and benzoylacetone complexes.

Disclosed is an electroplating solution for the deposition of silver; said solution containing silver in the form of a complex of silver with hydantoin or a substituted hydantoin compound; said solution also containing an excess of the hydantoin or substituted hydantoin compound employed, together with an effective quantity of a nonprecipitating electrolyte salt, and also an effective quantity of 2,2′ dipyridyl for the purpose of obtaining a mirror-bright to brilliant deposit.

The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I)wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors-subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

There is disclosed herein phosphorescent compounds, uses thereof, and devices including organic light emitting diode (OLEDs) including such compounds. Compounds of interest include: wherein A is Os or Ru The anionic chelating chromophores NˆN, which are formed by connecting one pentagonal ring structure containing at least two nitrogen atoms to a hexagonal pyridine type of fragment via a direct carbon-carbon linkage. L is a neutral donor ligand; the typical example includes carbonyl, pyridine, phosphine, arsine and isocyanide; two neutral L's can also combine to produce the so-called chelating ligand such as 2,2′-bipyridine, 1,10-phenanthroline and N-heterocyclic carbene (NHC) ligand, or bidentate phosphorous ligands such as 1,2-bis(diphenylphosphino)ethane, 1,2-bis(diphenylphosphino)benzene. L can occupy either cis or trans orientation. When L occupies the trans position, the preferred structure contains both the hexagonal fragment of NˆN as well as its pentagonal fragment located at the trans position respect to their counterparts of the second NˆN chromophore. When L occupies the cis position, the preferred structure consists of the pentagonal unit of NˆN chromophores residing opposite to the L. X,1 X2 and X3 independently are C or N; when X2 is N, R1 is omitted, when X3 is N, R2 is omitted, R1 is H, C1-C8 alkyl, C1-C8 substituted phenyl or C1-C4 perfluoroalkyl, R2 is H, F or cyano substituent, X4 is either C or N; X4 may locate at any position of the hexagonal ring, when X4 is N and R3 and R4 are not linked to X4, R3 is H, methyl or C1-C3 small alkyl, R4 is H, methyl or C1-C3 small alkyl, or R3 and R4 together form an additional conjugated unit with structure